RxDoctor Payments Data

Tagrid Adili, MD

Neurology · Port St Lucie, FLNPI 1093820417

Payments from drug & device makers

$13,360in general payments, 2019–2025

Across 537 payments — averaging $24.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$955
  • Biogen$840
  • Sanofi$765
  • Harmony Biosciences LLC$651
  • Jazz Pharmaceuticals Inc.$627
  • plus $8K from 46 others

What the payments were for

  • Speaking & faculty fees$260%
  • Food & beverage$13,01397%
  • Education$3202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,360 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$101,546
Medicare patients
295
Services billed
737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate12$263,190
Sodium Oxybate11$222,246
OctagamImmun Globg(Igg)/Malt/Iga Ov5011$113,889
QuliptaAtogepant22$38,108
Aimovig AutoinjectorErenumab-Aooe33$27,840
NeuproRotigotine14$25,328
BriviactBrivaracetam14$20,874
VimpatLacosamide13$19,558
Emgality PenGalcanezumab-Gnlm11$14,057
Duloxetine Hcl527$13,277
FingolimodFingolimod Hcl11$6,144
Topiramate209$3,820
Memantine Hcl77$2,533
Donepezil Hcl193$2,057
Levetiracetam61$1,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$379$113,88911 claims
UCB, Inc.Neupro, Briviact, Vimpat$538$65,76041 claims
AbbVieQulipta$1,432$38,10822 claims
Upsher-smith Laboratories LLCTopiramate$83$3,820209 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →